Fierce Pharma Asia—Boehringer’s $7.4B SBP deal; Fresenius’ sweeping biosim pact; A $1B molecular glue bet – Fierce Pharma
Boehringer’s $7.4B Stelis deal, Fresenius’ sweeping biosimilar pact and a bold $1B molecular glue push highlight Asia’s rising influence in global pharma strategy.